SG11202006087UA - Heterocyclylamino-substituted triazoles as modulators of rho-associated protein kinase - Google Patents
Heterocyclylamino-substituted triazoles as modulators of rho-associated protein kinaseInfo
- Publication number
- SG11202006087UA SG11202006087UA SG11202006087UA SG11202006087UA SG11202006087UA SG 11202006087U A SG11202006087U A SG 11202006087UA SG 11202006087U A SG11202006087U A SG 11202006087UA SG 11202006087U A SG11202006087U A SG 11202006087UA SG 11202006087U A SG11202006087U A SG 11202006087UA
- Authority
- SG
- Singapore
- Prior art keywords
- heterocyclylamino
- rho
- modulators
- protein kinase
- associated protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1801226.0A GB201801226D0 (en) | 2018-01-25 | 2018-01-25 | Modulators of Rho-associated protein kinase |
PCT/GB2019/050215 WO2019145729A1 (en) | 2018-01-25 | 2019-01-25 | Heterocyclylamino-substituted triazoles as modulators of rho-associated protein kinase |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202006087UA true SG11202006087UA (en) | 2020-08-28 |
Family
ID=61558335
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202006087UA SG11202006087UA (en) | 2018-01-25 | 2019-01-25 | Heterocyclylamino-substituted triazoles as modulators of rho-associated protein kinase |
Country Status (25)
Country | Link |
---|---|
US (2) | US11497751B2 (en) |
EP (2) | EP3743420B1 (en) |
JP (2) | JP2021512158A (en) |
KR (1) | KR20200113216A (en) |
CN (1) | CN111655681B (en) |
AU (1) | AU2019213214B2 (en) |
BR (1) | BR112020013759A2 (en) |
CA (1) | CA3088330A1 (en) |
CY (1) | CY1125017T1 (en) |
DK (1) | DK3743420T3 (en) |
EA (1) | EA202091711A1 (en) |
ES (1) | ES2907833T3 (en) |
GB (1) | GB201801226D0 (en) |
HR (1) | HRP20220269T8 (en) |
HU (1) | HUE058940T2 (en) |
IL (1) | IL275988B2 (en) |
LT (1) | LT3743420T (en) |
MX (1) | MX2020007898A (en) |
PH (1) | PH12020550986A1 (en) |
PL (1) | PL3743420T3 (en) |
PT (1) | PT3743420T (en) |
SG (1) | SG11202006087UA (en) |
SI (1) | SI3743420T1 (en) |
WO (1) | WO2019145729A1 (en) |
ZA (1) | ZA202003983B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201801226D0 (en) | 2018-01-25 | 2018-03-14 | Redx Pharma Plc | Modulators of Rho-associated protein kinase |
CN111718310B (en) * | 2019-08-19 | 2021-06-11 | 中国药科大学 | Phenyl-substituted five-membered heterocyclic compound, and preparation method, application and pharmaceutical composition thereof |
CN110845410B (en) * | 2019-10-29 | 2021-02-26 | 暨明医药科技(苏州)有限公司 | Method for preparing 6, 7-dimethoxy-3, 4-dihydroisoquinoline hydrochloride by one-pot method |
IL310209A (en) * | 2021-07-26 | 2024-03-01 | Harvard College | Rock2 inhibitors and uses thereof |
CN113999211B (en) * | 2021-11-23 | 2022-11-29 | 郑州大学 | Indazole skeleton derivative containing 1,2,3-triazole with specific activity of resisting prostate cancer |
GB202200735D0 (en) * | 2022-01-20 | 2022-03-09 | Redx Pharma Plc | Compounds |
WO2023182856A1 (en) * | 2022-03-24 | 2023-09-28 | 서울대학교산학협력단 | Pharmaceutical composition including rho-kinase inhibitor for prevention or treatment of cutaneous fibrotic disorders such as keloid, etc. and use thereof |
CN116891460A (en) * | 2023-07-12 | 2023-10-17 | 浙江大学 | Indazole derivative or pharmaceutically acceptable salt thereof and application thereof |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9207396D0 (en) | 1992-04-03 | 1992-05-13 | Merck Sharp & Dohme | Therapeutic agents |
CA2422371C (en) * | 2000-09-15 | 2010-05-18 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
TWI335913B (en) * | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
WO2004052280A2 (en) * | 2002-12-10 | 2004-06-24 | Imclone Systems Incorporated | Anti-angiogenic compounds and their use in cancer treatment |
EP1730124A4 (en) * | 2004-03-26 | 2009-04-01 | Amphora Discovery Corp | Certain triazole-based compounds, compositions, and uses thereof |
WO2006135383A2 (en) * | 2004-08-04 | 2006-12-21 | Myriad Genetics, Inc. | Indazoles |
TW200804314A (en) * | 2006-05-25 | 2008-01-16 | Synta Pharmaceuticals Corp | Triazole compounds that modulate Hsp90 activity |
DE102007022565A1 (en) | 2007-05-14 | 2008-11-20 | Merck Patent Gmbh | Heterocyclic indazole derivatives |
JP2011525892A (en) * | 2008-06-18 | 2011-09-29 | メルク・シャープ・エンド・ドーム・コーポレイション | JANUS kinase inhibitors |
WO2011119894A2 (en) * | 2010-03-24 | 2011-09-29 | Kinagen, Inc | Heterocyclic compounds useful for kinase inhibition |
WO2012045883A1 (en) | 2010-10-08 | 2012-04-12 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
RS55165B1 (en) * | 2010-12-20 | 2017-01-31 | Merck Serono Sa | Indazolyl triazole derivatives as irak inhibitors |
US20150011751A1 (en) * | 2012-03-09 | 2015-01-08 | Carna Biosciences, Inc. | Novel triazine derivative |
WO2016138335A1 (en) * | 2015-02-27 | 2016-09-01 | Lycera Corporation | Indazolyl thiadiazolamines and related compounds for inhibition of rho-associated protein kinase and the treatment of disease |
PE20220507A1 (en) | 2015-12-16 | 2022-04-07 | Loxo Oncology Inc | COMPOUNDS USEFUL AS KINASE INHIBITORS |
JP7039802B2 (en) * | 2017-06-30 | 2022-03-23 | ベイジン タイド ファーマシューティカル カンパニー リミテッド | Pharmaceutical composition containing RHO-related protein kinase inhibitor, RHO-related protein kinase inhibitor, preparation method and use of the pharmaceutical composition. |
GB201801226D0 (en) | 2018-01-25 | 2018-03-14 | Redx Pharma Plc | Modulators of Rho-associated protein kinase |
-
2018
- 2018-01-25 GB GBGB1801226.0A patent/GB201801226D0/en not_active Ceased
-
2019
- 2019-01-25 CA CA3088330A patent/CA3088330A1/en active Pending
- 2019-01-25 SG SG11202006087UA patent/SG11202006087UA/en unknown
- 2019-01-25 HU HUE19702694A patent/HUE058940T2/en unknown
- 2019-01-25 DK DK19702694.1T patent/DK3743420T3/en active
- 2019-01-25 HR HRP20220269TT patent/HRP20220269T8/en unknown
- 2019-01-25 ES ES19702694T patent/ES2907833T3/en active Active
- 2019-01-25 WO PCT/GB2019/050215 patent/WO2019145729A1/en active Application Filing
- 2019-01-25 EP EP19702694.1A patent/EP3743420B1/en active Active
- 2019-01-25 MX MX2020007898A patent/MX2020007898A/en unknown
- 2019-01-25 SI SI201930178T patent/SI3743420T1/en unknown
- 2019-01-25 PT PT197026941T patent/PT3743420T/en unknown
- 2019-01-25 LT LTEPPCT/GB2019/050215T patent/LT3743420T/en unknown
- 2019-01-25 CN CN201980010083.3A patent/CN111655681B/en active Active
- 2019-01-25 EP EP21214072.7A patent/EP4026834A1/en active Pending
- 2019-01-25 PL PL19702694T patent/PL3743420T3/en unknown
- 2019-01-25 EA EA202091711A patent/EA202091711A1/en unknown
- 2019-01-25 KR KR1020207022578A patent/KR20200113216A/en not_active Application Discontinuation
- 2019-01-25 BR BR112020013759-6A patent/BR112020013759A2/en unknown
- 2019-01-25 JP JP2020561950A patent/JP2021512158A/en active Pending
- 2019-01-25 AU AU2019213214A patent/AU2019213214B2/en active Active
- 2019-01-25 US US16/964,904 patent/US11497751B2/en active Active
-
2020
- 2020-06-25 PH PH12020550986A patent/PH12020550986A1/en unknown
- 2020-06-30 ZA ZA2020/03983A patent/ZA202003983B/en unknown
- 2020-07-12 IL IL275988A patent/IL275988B2/en unknown
-
2022
- 2022-02-16 CY CY20221100132T patent/CY1125017T1/en unknown
- 2022-08-26 US US17/896,626 patent/US11878020B2/en active Active
-
2023
- 2023-11-28 JP JP2023200631A patent/JP2024026193A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL275988A (en) | Heterocyclylamino-substituted triazoles as modulators of rho-associated protein kinase | |
IL287136B1 (en) | Inhibitors of receptor-interacting protein kinase 1 | |
ZA201805879B (en) | Inhibitors of wdr5 protein-protein binding | |
EP3177295A4 (en) | Uses of salt-inducible kinase (sik) inhibitors | |
EP3247692A4 (en) | Inhibitors of trka kinase | |
EP3423437A4 (en) | Inhibitors of wdr5 protein-protein binding | |
EP3668839A4 (en) | Heterocyclic inhibitors of atr kinase | |
EP3651768A4 (en) | Heterocyclic inhibitors of atr kinase | |
EP3679031A4 (en) | Inhibitors of wdr5 protein-protein binding | |
IL304110A (en) | Inhibitors of keap1-nrf2 protein-protein interaction | |
EP3262041A4 (en) | Indazolyl thiadiazolamines and related compounds for inhibition of rho-associated protein kinase and the treatment of disease | |
EP3675861A4 (en) | Inhibitors of rho associated coiled-coil containing protein kinase | |
EP3654970A4 (en) | Inhibitors of rho associated coiled-coil containing protein kinase | |
ZA202000107B (en) | Aminothiazole compounds as protein kinase inhibitors | |
IL283408A (en) | Pyrazoles as modulators of hemoglobin | |
ZA201808238B (en) | Certain protein kinase inhibitors | |
SG11202000621VA (en) | Inhibitors of ror? | |
EP3134390A4 (en) | Small molecule inhibitors of g protein coupled receptor 6 kinase polypeptides | |
EP3555092A4 (en) | Protein kinase inhibitors | |
EP3134399A4 (en) | Small molecule inhibitors of g protein coupled receptor 6 kinases polypeptides | |
EP3654972A4 (en) | Inhibitors of rho associated coiled-coil containing protein kinase | |
PL3632912T3 (en) | Pyridoquinazoline derivatives useful as protein kinase inhibitors | |
GB201700484D0 (en) | Modulators of Rho-associated protein kinase | |
GB201700490D0 (en) | Modulators of rho-associated protein kinase | |
GB201604633D0 (en) | Combination of control interfaces for multiple communicating domains |